The global fight against Human Immunodeficiency Virus (HIV) has reached a critical juncture, marked by the recent European Union (EU) approval of Gilead’s groundbreaking drug, Yeytuo (lenacapavir). This long-acting injectable drug for HIV prevention

Gilead Sciences’ announcement of the successful Phase III ASCENT-03 trial, in which Trodelvy (sacituzumab govitecan-hziy) demonstrated a significant improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC), represents a major development in the treatment of this aggressive disease.

Alright, let's dive into the world of hepatitis delta virus (HDV) and the latest buzz around bulevirtide. Gilead Sciences recently dropped the curtain on the final outcomes of their long-term trial, and folks in the medical community are definitely paying attention. HDV, as some might know, is a bit of a tricky customer. It's a virus that requires the hepatitis B virus (HBV) to even get going, which makes it a sort of parasitic virus.